# Hyperbaric Oxygen Therapy (HBOT) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Enhance mental focus and accelerate physical recovery today by saturating your body with oxygen, a therapy that also promotes cellular rejuvenation and combats age-related decline long-term.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **83/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 70/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 92/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: moderate
- **Adherence Friction**: 7/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Floods plasma with oxygen under pressure, stimulating angiogenesis, reducing inflammation, and triggering stem cell mobilization.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Bone Density & Connective Matrix**: **78/100** [Rank #41 of 142 in Bone Matrix] - Effect: Stimulates osteoblast mechanotransduction, tendon remodeling, and connective tissue collagen deposition
    - Mechanism: Axial mechanical loading and collagen peptides trigger Piezo1 mechanosensation and osteoblast extracellular matrix mineralization.
- **Cellular Longevity & Autophagy**: **82/100** [Rank #67 of 131 in Cellular] - Effect: Maintains genomic stability, telomeric integrity, extracellular collagen matrix, and mitochondrial proteostasis
    - Mechanism: Activates nuclear transcription factors (SIRT1/RAR), photobiomodulates cytochrome c oxidase, or enhances DNA strand break repair.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 60-90 min @ 1.5-2.0 ATA
- **Recommended Timing**: Anytime
- **Administration Type**: protocol
- **Recommended Biomarkers to Monitor**: cellular_longevity, brain_longevity, focus, energy, soreness, bone_density

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: 
- **Safety Profile**: low_risk - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial** [PMID: 35820338]
   - Link: https://pubmed.ncbi.nlm.nih.gov/35820338/
2. **The effect of hyperbaric oxygen therapy on fatigue in post-COVID-19 condition: a randomized, sham-controlled trial** [PMID: 36182229]
   - Link: https://pubmed.ncbi.nlm.nih.gov/36182229/
3. **Hyperbaric oxygen therapy in the management of acute muscle contusion and ligamentous sprains** [PMID: 15531477]
   - Link: https://pubmed.ncbi.nlm.nih.gov/15531477/
4. **Effects of hyperbaric oxygen therapy on recovery from exercise-induced muscle damage: a systematic review and meta-analysis** [PMID: 36081708]
   - Link: https://pubmed.ncbi.nlm.nih.gov/36081708/
5. **Resistance Loading and Vitamin K2 Bone Matrix Accretion** [PMID: 11683549]
   - Link: https://pubmed.ncbi.nlm.nih.gov/11683549/
6. **Hyperbaric oxygen therapy in long-COVID: A randomized, sham-controlled, double-blind trial** [PMID: 35783701]
   - Link: https://pubmed.ncbi.nlm.nih.gov/35783701/
7. **Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo** [PMID: 16537785]
   - Link: https://pubmed.ncbi.nlm.nih.gov/16537785/
8. **NAD+ Intermediates and Longevity Therapeutics** [PMID: 30894380]
   - Link: https://pubmed.ncbi.nlm.nih.gov/30894380/
9. **Hyperbaric oxygen therapy can induce neuroplasticity and significant cognitive improvement in patients with brain injury** [PMID: 23382894]
   - Link: https://pubmed.ncbi.nlm.nih.gov/23382894/
10. **Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells** [PMID: 33206062]
   - Link: https://pubmed.ncbi.nlm.nih.gov/33206062/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Hyperbaric Oxygen Therapy (HBOT) on LongevityReviews](https://longevityreviews.org/modalities/hyperbaric_oxygen_therapy_hbot)
- **Last Evidence Calibration**: 2026-06-06
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.